Biliary Tract Cancer

Common Name(s)

Biliary Tract Cancer

Bile Tract Cancer is a rare digestive cancer characterized by abnormal cell growth in the bile ducts and gallbladder. Individuals with this disorder may grow harmful tumors that can spread to the rest of the body if not diagnosed early. The bile duct system is responsible for storing and transporting bile from the liver, where it is made, to the intestines, where it helps to digest food. Incomplete development of the ducts inhibits the flow of bile. Individuals with this defect have digestion problems as well as a yellow discoloration of the eye and skin (jaundice). Doctors are usually able to diagnose this defect early in the abnormal growth process, as the resulting symptoms are quickly apparent. Treatment is developed on a case-by-case basis and depends on the specific needs of the patient. For prevention measures, digestion specialists may suggest individuals eat a lower-fat diet, or undergo surgery to relieve the blockage or create a tube to allow bile to reach the digestive system. If an individual's cancer has progressed, doctors may suggest chemotherapy to combat cancer symptoms.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Biliary Tract Cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Biliary Tract Cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Biliary Tract Cancer" returned 93 free, full-text research articles on human participants. First 3 results:

Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004).
 

Author(s): Masanori Toyoda, Tetsuo Ajiki, Yutaka Fujiwara, Hiroaki Nagano, Shogo Kobayashi, Daisuke Sakai, Etsuro Hatano, Masashi Kanai, Shoji Nakamori, Atsushi Miyamoto, Akihito Tsuji, Satoshi Kaihara, Hisashi Ikoma, Shigekazu Takemura, Hideyoshi Toyokawa, Hiroaki Terajima, Satoshi Morita, Tatsuya Ioka

Journal: Cancer Chemother. Pharmacol.. 2014 Jun;73(6):1295-301.

 

We conducted a phase I study to determine the maximum tolerated dose and recommended dose (RD) of this gemcitabine plus cisplatin (GC) combination in the adjuvant setting for biliary tract cancer (BTC). GC has become a standard chemotherapy regimen for patients with locally advanced ...

Last Updated: 26 May 2014

Go To URL
Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer.
 

Author(s): Atsushi Aruga, Nobuhiro Takeshita, Yoshihito Kotera, Ryuji Okuyama, Norimasa Matsushita, Takehiro Ohta, Kazuyoshi Takeda, Masakazu Yamamoto

Journal:

 

The prognosis of patients with advanced biliary tract cancer (BTC) is extremely poor and only a few standard treatments are available for this condition. We performed a phase I trial to investigate the safety, immune response and anti-tumor effect of vaccination with three peptides ...

Last Updated: 17 Mar 2014

Go To URL
Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer.
 

Author(s): Krasimira Aleksandrova, Heiner Boeing, Ute Nöthlings, Mazda Jenab, Veronika Fedirko, Rudolf Kaaks, Annekatrin Lukanova, Antonia Trichopoulou, Dimitrios Trichopoulos, Paolo Boffetta, Elisabeth Trepo, Sabine Westhpal, Talita Duarte-Salles, Magdalena Stepien, Kim Overvad, Anne Tjønneland, Jytte Halkjaer, Marie-Christine Boutron-Ruault, Laure Dossus, Antoine Racine, Pagona Lagiou, Christina Bamia, Vassiliki Benetou, Claudia Agnoli, Domenico Palli, Salvatore Panico, Rosario Tumino, Paolo Vineis, Bas Bueno-de-Mesquita, Petra H Peeters, Inger Torhild Gram, Eiliv Lund, Elisabete Weiderpass, J Ramón Quirós, Antonio Agudo, María-José Sánchez, Diana Gavrila, Aurelio Barricarte, Miren Dorronsoro, Bodil Ohlsson, Björn Lindkvist, Anders Johansson, Malin Sund, Kay-Tee Khaw, Nicholas Wareham, Ruth C Travis, Elio Riboli, Tobias Pischon

Journal: Hepatology. 2014 Sep;60(3):858-71.

 

Obesity and associated metabolic disorders have been implicated in liver carcinogenesis; however, there are little data on the role of obesity-related biomarkers on liver cancer risk. We studied prospectively the association of inflammatory and metabolic biomarkers with risks of hepatocellular ...

Last Updated: 26 Aug 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Biliary Tract Cancer" returned 6 free, full-text review articles on human participants. First 3 results:

Current status of chemotherapy for the treatment of advanced biliary tract cancer.
 

Author(s): Takashi Sasaki, Hiroyuki Isayama, Yousuke Nakai, Kazuhiko Koike

Journal: Korean J. Intern. Med.. 2013 Sep;28(5):515-24.

 

Chemotherapy is indispensable for the treatment of advanced biliary tract cancer. Recently, reports regarding first-line chemotherapy have increased, and first-line chemotherapy treatment has become gradually more sophisticated. Gemcitabine and cisplatin combination therapy (or gemcitabine ...

Last Updated: 6 Sep 2013

Go To URL
Current status of immunotherapy for the treatment of biliary tract cancer.
 

Author(s): Ryuji Takahashi, Munehiro Yoshitomi, Shigeru Yutani, Takahisa Shirahama, Masanori Noguchi, Akira Yamada, Kyogo Itoh, Tetsuro Sasada

Journal: Hum Vaccin Immunother. 2013 May;9(5):1069-72.

 

Biliary tract cancer (BTC) is one of the most aggressive malignancies. Although various promising regimens of chemotherapeutic and/or molecular targeted agents have been developed, further treatment modalities, including immunotherapies, still remain to be established for refractory ...

Last Updated: 7 Oct 2013

Go To URL
Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis.
 

Author(s): Anne M Horgan, Eitan Amir, Thomas Walter, Jennifer J Knox

Journal: J. Clin. Oncol.. 2012 Jun;30(16):1934-40.

 

The benefit of adjuvant therapy (AT) for biliary tract cancer (BTC) is unclear, with conflicting results from nonrandomized studies. We report a systematic review and meta-analysis to determine the impact of AT on survival.

Last Updated: 31 May 2012

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Second Line Therapy in Advanced Biliary Tract Cancer
 

Status: Recruiting

Condition Summary: Biliary Tract Cancer

 

Last Updated: 9 Feb 2012

Go to URL
Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma)
 

Status: Not yet recruiting

Condition Summary: Biliary Tract Cancer

 

Last Updated: 11 Aug 2010

Go to URL

Last Updated: 21 Oct 2014

Go to URL